The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
Open accessAbstract
Background: Recipients of solid organ transplant (SOT) are a high-risk group for severe SARS-CoV-2 infection. The mortality rate of patients with SOT during the COVID-19 pandemic has been reported to be approximately 20% (1). The anti–SARS-CoV-2 vaccines represent a hope to protect this population against this life-threatening infection.Objective: To assess the humoral response to messenger RNA (mRNA)–based vaccination in recipients of SOT.Methods: All patients with heart, kidney, liver, or pancreas transplants from the Midi-Pyrénées region (southwest France) are followed in our department. When the vaccination campaign started (7 January 2021), these patients were invited via text message, e-mail, or transplant patients' associations to be vaccinated. Patients were asked to register via a dedicated telephone number or website. They were vaccinated consecutively according to their registration date. According to the recommendations of the Francophone Society of Transplantation, anti–SARS-CoV-2 spike protein antibodies were monitored before and after vaccination. We used the SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay test (Beijing Wantai Biological Pharmacy Enterprise) (80% of patients) or another validated anti–SARS-CoV-2 spike protein assay. According to French law (loi Jardé), anonymous retrospective studies do not require institutional review board approval.Findings: By 16 April 2021, 950 patients of the 2666 from our cohort had received at least 1 dose of an mRNA vaccine (BNT162b2 vaccine [Pfizer-BioNTech], n = 942; mRNA-1273 vaccine [Moderna], n = 8) and had anti–SARS-CoV-2 antibodies monitored. Fifty patients had vaccination without monitoring of antibodies, 80 patients are planned to be vaccinated within the next month, and 257 patients declined the vaccine. We had no feedback from the remaining 1329 patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to the findings in other reports,17-19 a significantly lower antibody response was found consistently through the observation period among participants with immunosuppression, who had neutralizing antibody titers that were lower by a factor of 5 than those among participants without immunosuppression.”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [18]
Citations
Cites
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik‐Wang, J. (2021) · JAMA · doi:10.1001/jama.2021.4385 · Cited by 510
Grupper, A., Rabinowich, L., Schwartz, D., Schwartz, I. F., Ben‐Yehoyada, M., Shashar, M., Katchman, E. A., Halperin, T., Turner, D., Goykhman, Y., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16615 · Cited by 355
COVID-19 in solid organ transplant: A multi-center cohort study
Kates, O., Haydel, B., Florman, S., Rana, M., Chaudhry, Z., Ramesh, M., Safa, K., Kotton, C., Blumberg, E., Besharatian, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1097 · Cited by 351
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
Marinaki, S., Adamopoulos, S. N., Degiannis, D., Roussos, S., Pavlopoulou, I. D., Hatzakis, A. E., & Boletis, I. N. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16607 · Cited by 115
Flagged first, then by citations
Cited by
Sorted by citations
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., & Bello, A. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108861 · Cited by 810
Self-citationSun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A. J., Singh, J. A., French, E., Abraham, A. G., Mathew, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7024 · Cited by 257
Galmiche, S., Nguyen, L. B. L., Tartour, É., de Lamballerie, X. N., Wittkop, L., Loubet, P., & Launay, O. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.036 · Cited by 207
Bello, A. D., Abravanel, F., Marion, O., Couat, C., Esposito, L., Lavayssière, L., Izopet, J., & Kamar, N. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16775 · Cited by 128
Self-citation
Metadata
- Authors
- Marion, O., Del Bello, A., Abravanel, F., Couat, C., Faguer, S., Esposito, L., Hebral, A. L., Izopet, J., & Kamar, N.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- Toulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, France
- Hôpital Rangueil (FR)
- Toulouse Rangueil University Hospital, Toulouse, France
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2021-09
- Volume
- 174
- Issue
- 9
- Pages
- 1336-1338
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC8252830
- OpenAlex
- W3164162028
- Cited by
- 142
- References
- 5
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 12 · 2023: 22 · 2022: 63 · 2021: 37
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 vaccines, mRNA vaccines, solid organ transplant recipients, vaccine safety, immunogenicity, immunosuppression
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Viral, Female, Humans, Male, Middle Aged, Immunocompromised Host, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
